BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hussein RS, Tantawy W, Abbas YA. MRI assessment of hepatocellular carcinoma after locoregional therapy. Insights Imaging 2019;10:8. [PMID: 30694398 DOI: 10.1186/s13244-019-0690-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Meng F, Zou B, Yang R, Duan Q, Qian T. The diagnostic efficiency of the perfusion-related parameters in assessing the vascular disrupting agent (CA4P) response in a rabbit VX2 liver tumor model. Acta Radiol 2021;:2841851211032450. [PMID: 34279135 DOI: 10.1177/02841851211032450] [Reference Citation Analysis]
2 Abdel razek A, El-serougy L, Saleh G, Shabana W, Abd el-wahab R. Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy. Diagnostic and Interventional Imaging 2020;101:547-53. [DOI: 10.1016/j.diii.2020.03.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
3 Sun Y, Bai H, Xia W, Wang D, Zhou B, Zhao X, Yang G, Xu L, Zhang W, Liu P, Xu J, Meng S, Liu R, Gao X. Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI. J Magn Reson Imaging 2020;52:1083-90. [PMID: 32233054 DOI: 10.1002/jmri.27143] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
4 Zhang R, Mo WJ, Huang LS, Chen JT, Wu WZ, He WY, Feng ZB. Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma. Bioengineered 2021;12:855-74. [PMID: 33641617 DOI: 10.1080/21655979.2021.1890399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Han T, Duan Q, Yang R, Wang Y, Yin H, Meng F, Liu Y, Qian T. Monitoring the therapeutic efficacy of CA4P in the rabbit VX2 liver tumor using dynamic contrast-enhanced MRI. Diagn Interv Radiol 2021;27:587-94. [PMID: 34559047 DOI: 10.5152/dir.2021.20010] [Reference Citation Analysis]
6 Bartolotta TV, Terranova MC, Gagliardo C, Taibbi A. CEUS LI-RADS: a pictorial review. Insights Imaging. 2020;11:9. [PMID: 32020352 DOI: 10.1186/s13244-019-0819-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
7 Lin SY, Chen CM, Huang BS, Lai YC, Pan KT, Lin SM, Chu SY, Tseng JH. A preliminary study of hepatocellular carcinoma post proton beam therapy using MRI as an early prediction of treatment effectiveness. PLoS One 2021;16:e0249003. [PMID: 33755701 DOI: 10.1371/journal.pone.0249003] [Reference Citation Analysis]
8 Kampalath R, Tran-Harding K, Do RKG, Mendiratta-Lala M, Yaghmai V. Evaluation of Hepatocellular Carcinoma Treatment Response After Locoregional Therapy. Magn Reson Imaging Clin N Am 2021;29:389-403. [PMID: 34243925 DOI: 10.1016/j.mric.2021.05.013] [Reference Citation Analysis]
9 Amorim J, França M, Perez-girbes A, Torregrosa A, Martí-bonmatí L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol 2020;45:3119-28. [DOI: 10.1007/s00261-020-02470-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Wang SY, Yin L, Wang C, Ma MP. Atypical magnetic resonance imaging features and differential diagnosis of hepatocellular carcinoma. J Int Med Res 2020;48:300060520943415. [PMID: 33081554 DOI: 10.1177/0300060520943415] [Reference Citation Analysis]
11 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Reference Citation Analysis]